APOB and hyperthyroidism: Hyperthyroidism is known to reduce circulating levels of ApoB, a liver-derived apolipoprotein that reflects circulating atherogenic lipoproteins (very low density lipoprotein, intermediate-density lipoprotein, small dense LDL) (10,23) and administration of eprotirome, a liver-selective thyroid hormone receptor agonist, lowers circulating ApoB and triglyceride levels (24).